XML 14 R4.htm IDEA: XBRL DOCUMENT v3.25.2
UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($)
$ in Thousands
 3 Months Ended
Jul. 31, 2025
Jul. 31, 2024
Income Statement [Abstract]    
Revenue, Product and Service [Extensible List] Service [Member] Service [Member]
Oncology revenue $ 13,995 $ 14,061
Costs and operating expenses:    
Cost, Product and Service [Extensible List] Service [Member] Service [Member]
Cost of oncology revenue $ 7,995 $ 7,072
Research and development 2,082 1,454
Sales and marketing 1,855 1,679
General and administrative 2,570 2,527
Loss on disposal of equipment 20 0
Total costs and operating expenses 14,522 12,732
(Loss) income from operations (527) 1,329
Other income, net 75 5
(Loss) income before provision for income taxes (452) 1,334
Provision for income taxes 14 21
Net (loss) income (466) 1,313
Less: net loss attributable to noncontrolling interest 30 0
Net (loss) income attributable to Company's common shares $ (436) $ 1,313
Net (loss) income per common share outstanding    
basic (in dollars per share) $ (0.03) $ 0.10
diluted (in dollars per share) $ (0.03) $ 0.09
Weighted average common shares outstanding    
basic (in shares) 13,788,414 13,593,766
and diluted (in shares) 13,788,414 14,042,379